Roche Holding AGRHHBY announced encouraging results from a randomized, double blind, global multi centre phase III study (ORATORIO) on ocrelizumab for the treatment of patients suffering from primary progressive multiple sclerosis (PPMS). The study met its primary endpoint. In
Roche's Primary Progressive MS Drug Positive in Phase III
